Ask Chat GPT about mRNA

The questions your Doctor Should have Known the Answers to BEFORE offering their mRNA advice, Newspaper editorials and their Services.

The mRNA slide of the above graphic is meant to depict the intensely complicated Genetic workings of the human body ; a system that has natural mRNA produced throughout the body in different parts of the body all working together to maintain the health of the body. The falling wrenches depict external and synthetic Genetics that has Never evolved or been part of the complex human body and could never integrate without predictable unpredictability.

The question and answer with Chat GPT is meant to expand on just how big a risk the mRNA vaccines are on what is otherwise a beautifully fine tuned natural human genetic balance.

Ahead of the Chat with Chat GPT, below is an important 3 minute preliminary Video to watch to get a basic understanding of natural mRNA that comes from the cell’s nucleus:

The following questions bring out what can not be covered up with the frayed blanket of ad nauseum assurances that include;
Trust the Regulatory Authorities, review panels, strict procedural guidelines and the trials of the vaccine manufacturers themselves.

This Chat with GPT is one that leads to the inevitable conclusion that what the TGA released onto the Australian Public was a reprehensible and indefensible cluster bomb of immediate, medium- and long-term RISK on current and future generations of Australians for minimal to almost no benefit to the public or the healthy individual.

---

Question 1:
How many different types of cells are found in the human body and can you list them for me?

---

ChatGPT

The human body is composed of a wide variety of cell types, each specialized for different functions. While there isn't a single, universally agreed-upon number, it's generally accepted that there are about 200 different types of cells. Here's a list of some of the key types of cells:

1. Epithelial Cells:

• Squamous Epithelium: Thin, flat cells that line surfaces and cavities (e.g., skin, blood vessels).

• Cuboidal Epithelium: Cube-shaped cells found in glands and tubules (e.g., kidneys).

• Columnar Epithelium: Tall, column-shaped cells that line the digestive tract and other organs.

2. Connective Tissue Cells:

• Fibroblasts: Produce extracellular matrix and collagen.

• Adipocytes (Fat Cells): Store energy in the form of fat.

• Chondrocytes: Found in cartilage, maintain the cartilage matrix.

• Osteocytes: Found in bone, maintain bone tissue.

• Macrophages: Engulf and digest pathogens and debris.

• Mast Cells: Involved in inflammatory responses and allergy.

3. Muscle Cells:

• Skeletal Muscle Cells (Fibers): Voluntary muscles attached to bones.

• Cardiac Muscle Cells: Found in the heart, responsible for pumping blood.

• Smooth Muscle Cells: Involuntary muscles found in walls of internal organs like the stomach and intestines.

4. Nerve Cells (Neurons):

• Sensory Neurons: Transmit sensory information to the central nervous system.

• Motor Neurons: Transmit commands from the central nervous system to muscles and glands.

• Interneurons: Connect various neurons within the central nervous system.

5. Blood Cells:

• Red Blood Cells (Erythrocytes): Carry oxygen from the lungs to the rest of the body.

• White Blood Cells (Leukocytes): Part of the immune system; includes lymphocytes, neutrophils, and others.

• Platelets (Thrombocytes): Involved in blood clotting.

6. Reproductive Cells:

• Sperm Cells: Male reproductive cells involved in fertilization.

• Oocytes (Egg Cells): Female reproductive cells involved in fertilization.

7. Other Specialized Cells:

• Endothelial Cells: Line blood vessels and lymphatic vessels.

• Retinal Cells: Found in the retina, involved in vision.

• Pancreatic Beta Cells: Produce insulin in the pancreas.

Each of these cell types plays a critical role in maintaining the complex functions and homeostasis of the human body.

---

Question 2

Could you expand on the list to include all or most of the approximately 200 generally accepted cell types and group them?

---

ChatGPT

Certainly! The human body consists of a vast array of cell types, each with specialized functions. Here’s a more detailed and categorized list, covering many of the approximately 200 cell types generally recognized:

1. Epithelial Cells

• Simple Squamous Epithelium:

  • Endothelial Cells: Line blood vessels and lymphatics.

  • Mesothelial Cells: Line body cavities (e.g., pleura, peritoneum).

• Simple Cuboidal Epithelium:

  • Kidney Tubule Cells: Line kidney tubules.

  • Thyroid Follicular Cells: Produce thyroid hormones.

• Simple Columnar Epithelium:

  • Intestinal Epithelial Cells: Line the digestive tract.

  • Goblet Cells: Produce mucus in the intestines and respiratory tract.

• Stratified Squamous Epithelium:

  • Keratinized Cells: Skin surface cells.

  • Non-Keratinized Cells: Line moist surfaces (e.g., mouth, esophagus).

• Stratified Cuboidal Epithelium:

  • Sweat Gland Duct Cells: Line sweat gland ducts.

• Stratified Columnar Epithelium:

  • Found in some ducts and reproductive structures.

• Pseudostratified Columnar Epithelium:

  • Ciliated Cells: Line the respiratory tract and aid in mucus movement.

2. Connective Tissue Cells

• Fibrous Connective Tissue:

  • Fibroblasts: Produce extracellular matrix and collagen.

  • Myofibroblasts: Involved in wound healing.

• Adipose Tissue Cells:

  • White Adipocytes: Store energy as fat.

  • Brown Adipocytes: Involved in thermogenesis.

• Cartilage Cells:

  • Chondrocytes: Maintain cartilage matrix.

  • Chondroblasts: Produce cartilage matrix.

• Bone Cells:

  • Osteocytes: Maintain bone tissue.

  • Osteoblasts: Build bone tissue.

  • Osteoclasts: Resorb bone tissue.

• Blood Cells:

  • Erythrocytes (Red Blood Cells): Carry oxygen.

  • Leukocytes (White Blood Cells): Immune function (e.g., neutrophils, lymphocytes, monocytes).

  • Platelets (Thrombocytes): Blood clotting.

• Other Connective Tissue Cells:

  • Mast Cells: Release histamine and other mediators in inflammatory responses.

  • Macrophages: Engulf pathogens and debris.

  • Plasma Cells: Produce antibodies.

3. Muscle Cells

• Skeletal Muscle Cells:

  • Type I Fibers (Slow-Twitch): Endurance muscles.

  • Type II Fibers (Fast-Twitch): Power and speed muscles.

• Cardiac Muscle Cells:

  • Cardiomyocytes: Contract to pump blood.

• Smooth Muscle Cells:

  • Found in walls of organs such as the intestines, blood vessels, and bladder.

4. Nervous Tissue Cells

• Neurons:

  • Sensory Neurons: Transmit sensory information.

  • Motor Neurons: Control muscle movements.

  • Interneurons: Connect neurons within the central nervous system.

• Supporting Cells:

  • Astrocytes: Support and regulate neurons in the central nervous system.

  • Oligodendrocytes: Produce myelin in the central nervous system.

  • Schwann Cells: Produce myelin in the peripheral nervous system.

  • Microglia: Act as immune cells in the central nervous system.

  • Ependymal Cells: Line the ventricles of the brain and produce cerebrospinal fluid.

5. Reproductive Cells

• Male Reproductive Cells:

  • Spermatocytes: Precursor to sperm cells.

  • Spermatids: Intermediate stage in sperm development.

    • Spermatozoa (Sperm Cells): Male gametes.

• Female Reproductive Cells:

  • Oocytes (Egg Cells): Female gametes.

  • Granulosa Cells: Surround oocytes in ovarian follicles.

6. Endocrine Cells

• Pituitary Gland Cells:

  • Somatotrophs: Produce growth hormone.

  • Corticotrophs: Produce adrenocorticotropic hormone.

  • Thyrotrophs: Produce thyroid-stimulating hormone.

  • Gonadotrophs: Produce luteinizing hormone and follicle-stimulating hormone.

• Thyroid Gland Cells:

  • Follicular Cells: Produce thyroid hormones.

  • Parafollicular Cells (C Cells): Produce calcitonin.

• Adrenal Gland Cells:

  • Adrenal Cortex Cells: Produce corticosteroids.

  • Adrenal Medulla Cells: Produce adrenaline and norepinephrine.

• Pancreatic Cells:

  • Alpha Cells: Produce glucagon.

  • Beta Cells: Produce insulin.

  • Delta Cells: Produce somatostatin.

7. Specialized Sensory Cells

• Retinal Cells:

  • Rod Cells: Detect low light levels.

  • Cone Cells: Detect color and detail.

• Auditory Cells:

  • Hair Cells: Detect sound waves in the cochlea.

• Olfactory Cells:

  • Olfactory Receptor Neurons: Detect odors.

8. Other Specialized Cells

• Endothelial Cells: Line blood vessels and lymphatics.

• Melanocytes: Produce pigment in the skin.

• Keratinocytes: Produce keratin in the skin.

• Hepatocytes: Liver cells involved in metabolism and detoxification.

• Goblet Cells: Secrete mucus in various mucous membranes.

This list represents a broad overview, and many cells have subtypes or variations depending on their specific roles and locations within the body. Each of these cell types is crucial for the body's complex and coordinated functions.

---

Question 3

Of the above listed cell types can you list them again with the addition of whether it is known that these cell types produce proteins via mRNA from their nucleus along with the function of the proteins they produce?

---

ChatGPT

Certainly! Most cells in the human body produce proteins using mRNA transcribed from their DNA in the nucleus. Here’s a revised list of the cell types from above, including whether they produce proteins via mRNA and the general functions of these proteins:

1. Epithelial Cells

• Simple Squamous Epithelium:

  • Endothelial Cells: Produce proteins like endothelial nitric oxide synthase (eNOS) which helps in regulating blood vessel dilation and blood flow.

  • Mesothelial Cells: Produce proteins such as those involved in lubricating body cavities, like mesothelin.

• Simple Cuboidal Epithelium:

  • Kidney Tubule Cells: Produce proteins like aquaporins (water channels) which are crucial for water reabsorption.

  • Thyroid Follicular Cells: Produce thyroid hormones (thyroxine, T3) which regulate metabolism.

• Simple Columnar Epithelium:

  • Intestinal Epithelial Cells: Produce digestive enzymes and mucus (e.g., enterokinase, mucin) to aid in digestion and protect the lining of the intestines.

  • Goblet Cells: Produce mucus (mucins) to lubricate and protect mucous membranes.

• Stratified Squamous Epithelium:

  • Keratinized Cells: Produce keratin, a structural protein that provides protection and strength to the skin.

  • Non-Keratinized Cells: Produce mucins and other proteins that protect and lubricate moist surfaces.

• Stratified Cuboidal Epithelium:

  • Sweat Gland Duct Cells: Produce proteins involved in electrolyte transport and sweat formation.

• Stratified Columnar Epithelium:

  • Found in some ducts and reproductive structures: Produce proteins involved in secretion and protection.

• Pseudostratified Columnar Epithelium:

  • Ciliated Cells: Produce proteins such as dynein and other ciliary components to help move mucus and particles out of the respiratory tract.

2. Connective Tissue Cells

• Fibrous Connective Tissue:

  • Fibroblasts: Produce extracellular matrix proteins like collagen, elastin, and proteoglycans which provide structural support to tissues.

  • Myofibroblasts: Produce collagen and other extracellular matrix components involved in wound healing and tissue repair.

• Adipose Tissue Cells:

  • White Adipocytes: Produce leptin, a hormone involved in regulating energy balance and appetite.

  • Brown Adipocytes: Produce uncoupling protein-1 (UCP1) which is involved in thermogenesis (heat production).

• Cartilage Cells:

  • Chondrocytes: Produce cartilage matrix proteins like collagen type II and proteoglycans that maintain cartilage structure and function.

  • Chondroblasts: Produce matrix components that contribute to cartilage formation and repair.

• Bone Cells:

  • Osteocytes: Produce proteins involved in bone maintenance, including sclerostin, which regulates bone formation.

  • Osteoblasts: Produce bone matrix proteins like collagen type I and osteocalcin involved in bone formation.

  • Osteoclasts: Produce enzymes like cathepsin K involved in bone resorption.

• Blood Cells:

  • Erythrocytes (Red Blood Cells): Produce hemoglobin, a protein that transports oxygen.

  • Leukocytes (White Blood Cells): Produce various proteins for immune responses (e.g., antibodies by plasma cells, cytokines by macrophages).

  • Platelets (Thrombocytes): Produce clotting factors like fibrinogen and thromboxane to aid in blood clotting.

• Other Connective Tissue Cells:

  • Mast Cells: Produce histamine and heparin, which are involved in allergic responses and inflammation.

  • Macrophages: Produce cytokines and enzymes (e.g., interleukins, lysozymes) for immune defense and tissue repair.

  • Plasma Cells: Produce antibodies (immunoglobulins) for immune responses.

3. Muscle Cells

• Skeletal Muscle Cells:

  • Type I Fibers (Slow-Twitch): Produce proteins like myoglobin and various oxidative enzymes for endurance.

  • Type II Fibers (Fast-Twitch): Produce proteins like myosin and ATPase for rapid, powerful contractions.

• Cardiac Muscle Cells:

  • Cardiomyocytes: Produce proteins such as contractile proteins (actin, myosin) and structural proteins (titin) for heart contraction and structure.

• Smooth Muscle Cells:

  • Found in walls of organs: Produce proteins involved in contraction and relaxation, including smooth muscle actin and myosin.

4. Nervous Tissue Cells

• Neurons:

  • Sensory Neurons: Produce sensory receptors and neurotransmitters (e.g., glutamate, substance P) for transmitting sensory information.

  • Motor Neurons: Produce neurotransmitters (e.g., acetylcholine) to stimulate muscle contractions.

  • Interneurons: Produce neurotransmitters and modulatory proteins involved in complex brain functions and reflexes.

• Supporting Cells:

  • Astrocytes: Produce various proteins including those involved in maintaining the blood-brain barrier and neurotransmitter regulation (e.g., glutamate transporters).

  • Oligodendrocytes: Produce myelin sheath proteins (e.g., myelin basic protein) for insulating neuronal axons.

  • Schwann Cells: Produce myelin sheath proteins (e.g., myelin basic protein) in the peripheral nervous system.

  • Microglia: Produce cytokines and growth factors involved in immune responses and neuronal support.

  • Ependymal Cells: Produce cerebrospinal fluid and proteins involved in its secretion.

5. Reproductive Cells

• Male Reproductive Cells:

  • Spermatocytes: Produce proteins involved in sperm maturation.

  • Spermatids: Produce proteins necessary for sperm development and function.

  • Spermatozoa (Sperm Cells): Produce proteins such as acrosin, involved in penetrating the egg during fertilization.

• Female Reproductive Cells:

  • Oocytes (Egg Cells): Produce proteins involved in early embryonic development and fertilization.

  • Granulosa Cells: Produce hormones (e.g., estrogen) and proteins involved in follicle development and ovulation.

6. Endocrine Cells

• Pituitary Gland Cells:

  • Somatotrophs: Produce growth hormone (GH) for growth and metabolism.

  • Corticotrophs: Produce adrenocorticotropic hormone (ACTH) to stimulate cortisol production.

  • Thyrotrophs: Produce thyroid-stimulating hormone (TSH) to regulate thyroid function.

  • Gonadotrophs: Produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to regulate reproductive function.

• Thyroid Gland Cells:

  • Follicular Cells: Produce thyroid hormones (T3 and T4) that regulate metabolism.

  • Parafollicular Cells (C Cells): Produce calcitonin, which regulates calcium levels in the blood.

• Adrenal Gland Cells:

  • Adrenal Cortex Cells: Produce corticosteroids (e.g., cortisol) for stress response and metabolism.

  • Adrenal Medulla Cells: Produce catecholamines (e.g., adrenaline, norepinephrine) for the fight-or-flight response.

  • Pancreatic Cells:

    • Alpha Cells: Produce glucagon to increase blood glucose levels.

    • Beta Cells: Produce insulin to lower blood glucose levels.

    • Delta Cells: Produce somatostatin to regulate other hormone secretions.

7. Specialized Sensory Cells

• Retinal Cells:

  • Rod Cells: Produce proteins like rhodopsin involved in low-light vision.

  • Cone Cells: Produce photopsins involved in color vision.

• Auditory Cells:

  • Hair Cells: Produce proteins involved in mechanotransduction of sound vibrations.

• Olfactory Cells:

  • Olfactory Receptor Neurons: Produce olfactory receptors that bind to odor molecules and initiate smell perception.

8. Other Specialized Cells

• Endothelial Cells: Produce proteins like von Willebrand factor for blood clotting and various growth factors.

• Melanocytes: Produce melanin, a pigment involved in skin color and protection from UV radiation.

• Keratinocytes: Produce keratin, a structural protein that strengthens the skin and protects against environmental damage.

• Hepatocytes: Produce a wide array of proteins including albumin, clotting factors, and enzymes involved in metabolism.

• Goblet Cells: Produce mucins for mucus formation.

Each of these cell types synthesizes a specific set of proteins necessary for their specialized functions, and these proteins are crucial for maintaining the body's overall health and homeostasis.

When a cell receives mRNA instructions to produce a protein, several key resources and organelles are involved in the process. Here's a breakdown of these resources and the potential for their depletion and need for replenishment:

**1. Resources and Organelles Involved in Protein Production

**a. Nucleus:

• mRNA Synthesis: The nucleus transcribes DNA into mRNA. This involves RNA polymerase and various transcription factors.

• RNA Processing: Pre-mRNA undergoes splicing, capping, and polyadenylation before it exits the nucleus.

**b. Cytoplasm:

• Ribosomes: These are the molecular machines that translate mRNA into protein. Ribosomes can be free in the cytoplasm or attached to the endoplasmic reticulum (ER), forming the rough ER.

• tRNA (Transfer RNA): tRNAs bring amino acids to the ribosome based on the codon sequence of the mRNA.

• Amino Acids: These are the building blocks of proteins. Amino acids are transported into the cell and assembled into proteins by ribosomes.

**c. Endoplasmic Reticulum (ER):

• Rough ER: Studded with ribosomes, it helps in the synthesis and initial folding of proteins destined for secretion or membrane incorporation.

• Smooth ER: Involved in lipid synthesis and, in some cases, detoxification processes that can indirectly support protein production.

**d. Golgi Apparatus:

• Protein Modification and Sorting: Proteins synthesized in the ER are modified (e.g., glycosylation) and sorted for transport to their final destinations.

**e. Other Cellular Resources:

• ATP (Adenosine Triphosphate): Provides the energy required for various steps in protein synthesis, including the translation process and protein folding.

• Chaperone Proteins: Assist in the proper folding and assembly of proteins. They help prevent misfolding and aggregation.

**2. Depletion and Replenishment

**a. Ribosomes:

• Depletion: Ribosomes are not typically depleted quickly, but their availability can be impacted by cellular stress or damage.

• Replenishment: Ribosomal components are continually synthesized in the nucleolus and assembled into ribosomes.

**b. tRNA and Amino Acids:

• Depletion: tRNA molecules and amino acids can become depleted, particularly during high levels of protein synthesis or in cases of nutrient deficiency.

• Replenishment: Cells actively import amino acids from the bloodstream and synthesize tRNAs in the nucleolus.

**c. ATP:

• Depletion: ATP levels can be depleted by high-energy demands, including intensive protein synthesis.

• Replenishment: ATP is regenerated through cellular respiration (glycolysis, the citric acid cycle, and oxidative phosphorylation) in the mitochondria.

**d. Chaperone Proteins:

• Depletion: Chaperones can become overwhelmed or depleted under high levels of protein synthesis or stress conditions.

• Replenishment: Chaperone proteins are synthesized in the cell and their production can be upregulated in response to stress signals (e.g., heat shock proteins).

**e. mRNA:

• Depletion: mRNA levels are regulated and can be degraded or reduced depending on cellular needs and regulatory mechanisms.

• Replenishment: New mRNA is synthesized from DNA in the nucleus as required for continued protein production.

Cellular Adaptations

**1. Regulation of Protein Synthesis:

• Feedback Mechanisms: Cells have feedback mechanisms to regulate the rate of protein synthesis based on availability of resources and cellular needs.

• Stress Responses: Under stress, cells may activate stress responses (e.g., heat shock response) to protect and restore protein synthesis machinery.

**2. Nutrient and Energy Management:

• Nutrient Uptake: Cells regulate the uptake of amino acids and other nutrients from the environment to ensure a supply for protein synthesis.

• Energy Production: Mitochondrial function is crucial for maintaining adequate ATP levels for protein synthesis.

In summary, the process of protein synthesis in cells relies on a complex network of resources, including ribosomes, tRNA, amino acids, ATP, and chaperone proteins. While these resources can become depleted, cells have mechanisms to replenish them and ensure continued protein production.

---

Question 4

What is the longest time that any Natural mRNA instruction from a cell’s nucleus in a Human will remain active and ,if there is a natural time limit, does this help avoid depletion of resources to ensure continued protein production ?

---

ChatGPT

The lifespan of mRNA in human cells can vary significantly depending on the type of mRNA and its role in the cell. Here’s a detailed look at how long natural mRNA instructions remain active, factors influencing mRNA stability, and how this impacts resource management:

**1. mRNA Lifespan

**a. Short-Lived mRNAs:

• Transient Instructions: Many mRNAs, particularly those encoding regulatory proteins, transcription factors, or signaling molecules, have relatively short lifespans, ranging from minutes to a few hours. For example, mRNAs involved in cellular stress responses or immediate early genes often degrade quickly after their function is fulfilled.

• Examples: mRNA for cytokines or immediate-early genes (such as those induced by growth factors) often have half-lives on the order of minutes to a few hours.

**b. Moderately Stable mRNAs:

• Regulatory Proteins: Some mRNAs, encoding proteins required for ongoing cellular functions, have half-lives ranging from several hours to a day or more. These include mRNAs for metabolic enzymes or structural proteins that are needed consistently but not at the highest rates.

• Examples: mRNA for metabolic enzymes and structural proteins can have half-lives ranging from a few hours to around 24 hours.

**c. Long-Lived mRNAs:

• Constitutive Functions: mRNAs encoding proteins essential for core cellular functions, such as ribosomal proteins or certain housekeeping enzymes, can be more stable, often lasting from several hours to a few days.

• Examples: mRNA for ribosomal proteins and housekeeping enzymes like glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can have longer half-lives.

**2. Regulation and Degradation

**a. Decay Mechanisms:

• Exonucleases: mRNA degradation is often mediated by exonucleases that degrade mRNA from the 5' cap or the 3' poly(A) tail.

• Endonucleases: These can cleave mRNA internally, leading to degradation.

• Regulatory Sequences: Elements such as AU-rich elements (AREs) in the 3' untranslated region (UTR) of mRNA can influence its stability and degradation rate.

**b. Protective Mechanisms:

• mRNA Capping and Polyadenylation: These features protect mRNA from degradation and enhance translation efficiency.

• RNA-binding Proteins: Proteins that bind to mRNA can stabilize or destabilize it, influencing its lifespan and translation.

**3. Impact on Resource Management

**a. Avoiding Resource Depletion:

• Short-Lived mRNAs: The degradation of short-lived mRNAs helps prevent the continuous production of proteins that are only needed transiently, thereby avoiding excessive consumption of cellular resources.

• Regulated Synthesis: By controlling the synthesis and degradation of mRNA, cells can manage their protein production resources more efficiently.

**b. Resource Replenishment:

• Continued Production: While mRNA molecules are actively translated into proteins, the cell continuously synthesizes new mRNA as needed. This ongoing process helps balance resource use and ensures that proteins are produced according to current cellular demands.

• Regulatory Feedback: Cells employ feedback mechanisms to modulate mRNA production and degradation rates, thereby optimizing resource utilization.

**c. Long-Lived mRNAs:

• Efficient Utilization: Long-lived mRNAs contribute to the production of proteins that are required over extended periods, ensuring that essential functions are sustained without frequent replenishment of mRNA.

**4. Practical Examples

• Housekeeping Genes: mRNAs for housekeeping genes, such as those encoding ribosomal proteins, often have longer half-lives to ensure consistent protein production necessary for basic cellular functions.

• Immediate Early Genes: These mRNAs, such as those involved in stress responses or initial signaling events, are rapidly degraded after their function is complete to quickly adapt to changing conditions.

In summary, natural mRNA instructions in human cells can remain active for varying lengths of time, from minutes to several days, depending on their function and regulation. This variability in mRNA stability helps cells manage their resources effectively, ensuring that protein production is well-coordinated with cellular needs and minimizing the risk of resource depletion.

---

Question 5

What are the possible health consequences if mRNA that lasted for up to several months and was introduced in unregulated quantities were to enter into the above listed cell types where the mRNA instruction was to produce a protein that is known to damage the lining of blood vessels and is known to result in autoimmune disorders?

---

ChatGPT

If mRNA were to remain active for several months and instruct cells to produce a protein that damages the lining of blood vessels and causes autoimmune disorders, several serious health consequences could arise. Here’s a breakdown of the potential impacts:

**1. Damage to Blood Vessel Linings

**a. Increased Risk of Vascular Damage:

• Endothelial Cells: If mRNA instructs endothelial cells to produce a protein that damages the blood vessel lining, it could lead to endothelial dysfunction. This dysfunction may result in increased permeability of blood vessels, promoting inflammation and atherosclerosis (hardening of arteries).

• Consequences: Chronic endothelial damage can contribute to the development of cardiovascular diseases, such as hypertension, heart attack, and stroke.

**b. Disruption of Vascular Integrity:

• Blood Clotting: Damage to endothelial cells can disturb normal blood clotting processes, potentially leading to inappropriate clot formation (thrombosis) or bleeding disorders.

**2. Autoimmune Disorders

**a. Induction of Autoimmunity:

• Immune System Activation: The production of a protein that is harmful to self-tissues could provoke an immune response where the body starts to attack its own cells. This is particularly problematic if the protein resembles self-antigens or induces the presentation of altered self-antigens.

• Consequences: Autoimmune disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, or vasculitis could develop, leading to chronic inflammation, tissue damage, and systemic symptoms.

**b. Immune Complex Formation:

• Immune Complex Diseases: If the protein induces the formation of immune complexes (antigen-antibody complexes), these can deposit in tissues and cause damage. For example, immune complexes deposited in the kidneys can lead to glomerulonephritis.

**3. General Health Implications

**a. Chronic Inflammation:

• Ongoing Immune Response: Prolonged expression of a damaging protein can result in sustained inflammation, contributing to various inflammatory conditions and potentially leading to chronic disease states.

**b. Tissue Damage and Organ Dysfunction:

• Local Damage: Continuous protein production could result in localized tissue damage in the organs where the mRNA is expressed, affecting their normal function. For instance, persistent damage to the lungs, skin, or kidneys could impair their ability to function properly.

**c. Potential for Systemic Effects:

• Systemic Autoimmune Reactions: Systemic autoimmune reactions could lead to widespread symptoms affecting multiple organs and systems, potentially resulting in multi-organ failure in severe cases.

**4. Regulatory and Safety Considerations

**a. Controlled mRNA Expression:

• Normal Cellular Regulation: In a healthy system, mRNA production and degradation are tightly regulated to avoid such prolonged effects. Cellular mechanisms normally ensure that mRNA is not overexpressed or persistently active unless required.

**b. Potential for Adverse Effects:

• Unregulated Expression: Introducing mRNA in unregulated quantities can bypass natural control mechanisms, leading to abnormal protein production and potential toxic effects.

**c. Research and Monitoring:

• Safety Protocols: mRNA-based therapies and vaccines are rigorously tested for safety and efficacy in clinical trials. Continuous monitoring ensures that any unexpected adverse effects are detected and managed.

In summary, if mRNA that directs the production of a protein known to damage blood vessel linings and induce autoimmune disorders were to remain active for several months, it could lead to serious health consequences, including cardiovascular diseases, autoimmune disorders, chronic inflammation, and organ dysfunction. Regulatory mechanisms in cells and rigorous safety protocols in mRNA research and therapeutics are crucial to preventing such outcomes and ensuring that mRNA-based treatments are both effective and safe.

---

Question 6

If a mRNA-based treatment, involving the production of a protein known to damage the lining of blood vessels and known to result in autoimmune disorders, were to have a known uncontrolled biodistribution for a known uncontrolled duration of mRNA activity , other than through extensive clinical trials covering short, medium and long term outcomes with specific reference to the myriad of outcomes covered above, is there any other credible way to assert the treatment to be safe ?

---

ChatGPT

Ensuring the safety of an mRNA-based treatment, especially one involving the production of a protein known to have potentially harmful effects, involves multiple layers of assessment beyond just extensive clinical trials. While clinical trials are a crucial component, additional strategies and measures can contribute to evaluating and asserting the safety of such a treatment:

**1. Preclinical Research and Modeling

**a. In Vitro Studies:

• Cell Culture Models: Conduct detailed studies using various cell lines to assess the effects of the protein on cellular functions and health. This can provide initial insights into potential damage and mechanisms of toxicity.

• Toxicity Screening: Use assays to evaluate potential cytotoxicity, genotoxicity, and impacts on cellular signaling pathways.

**b. In Vivo Studies:

• Animal Models: Employ animal models to study the biodistribution, pharmacokinetics, and long-term effects of the mRNA treatment. This helps in identifying potential adverse effects before human trials.

• Tissue-Specific Analysis: Assess how the protein affects specific tissues and organs in animals, which can provide insights into potential risks.

**c. Bioinformatics and Computational Modeling:

• Protein Modeling: Use computational tools to predict the structure and function of the protein and potential off-target effects.

• Pathway Analysis: Model how the protein might interact with cellular pathways and contribute to adverse outcomes.

**2. Advanced Safety Monitoring Techniques

**a. Biodistribution Studies:

• Real-Time Imaging: Utilize advanced imaging techniques (e.g., PET, MRI) to monitor the biodistribution of mRNA and its protein product in real-time, tracking where they accumulate in the body.

• Biomarker Analysis: Measure biomarkers that indicate potential damage or systemic effects, helping to track the treatment's impact on different organs.

**b. Long-Term Monitoring:

• Extended Animal Studies: Continue monitoring animal models for extended periods to observe any delayed or chronic effects that may not be apparent in shorter-term studies.

• Ongoing Surveillance: Implement systems for continuous safety monitoring in clinical trials, including regular health check-ups and diagnostic tests.

**3. Regulatory and Safety Frameworks

**a. Regulatory Guidelines:

• Adherence to Guidelines: Follow established regulatory guidelines from agencies such as the FDA, EMA, or other relevant bodies, which provide comprehensive frameworks for evaluating mRNA therapies.

• Pre-Approval Consultation: Engage in pre-approval discussions with regulatory agencies to ensure all safety concerns are addressed before clinical trials.

**b. Post-Marketing Surveillance:

• Phase IV Trials: Conduct post-marketing studies to monitor the treatment's safety in a broader population over a longer term.

• Risk Management Plans: Develop and implement risk management plans, including strategies for managing adverse events and ensuring patient safety.

**4. Ethical and Independent Review

**a. Ethics Committees:

• Independent Review: Subject the treatment to review by independent ethics committees to ensure that the study design and risk management strategies are sound.

• Informed Consent: Ensure that informed consent processes adequately address potential risks and uncertainties, providing transparency to participants.

**b. Patient and Community Engagement:

• Stakeholder Feedback: Engage with patient advocacy groups and community stakeholders to understand their concerns and incorporate feedback into safety assessments.

**5. Contingency Planning and Risk Mitigation

**a. Contingency Plans:

• Emergency Protocols: Develop protocols for managing potential adverse effects that may arise during or after treatment.

• Dose Adjustments: Include plans for adjusting doses or discontinuing treatment if significant safety issues are detected.

**b. Data Sharing and Transparency:

• Open Data Sharing: Share data transparently with the scientific and medical communities to facilitate peer review and independent assessment of safety.

Summary

While clinical trials are essential for evaluating the safety of an mRNA-based treatment, especially one with potential risks, several additional strategies can bolster safety assurance. These include thorough preclinical research, advanced safety monitoring techniques, adherence to regulatory guidelines, ethical review, and risk mitigation planning. Combining these approaches with robust clinical trials helps to ensure a comprehensive assessment of the treatment’s safety and efficacy.

---

Question 7

In the absence of extensive clinical trials covering short-, medium- and long-term outcomes with specific reference to the myriad of outcomes covered above are the other measures sufficient to ensure safety of a proposed mRNA therapy

---

ChatGPT

In the absence of extensive clinical trials, ensuring the safety of a proposed mRNA therapy is challenging but not impossible. While clinical trials are the gold standard for evaluating the safety and efficacy of medical treatments, several other measures can provide important insights and contribute to the overall safety assessment. However, these measures may not fully substitute for the comprehensive data provided by clinical trials. Here’s an overview of alternative and complementary safety assessment measures:

**1. Preclinical Research

**a. In Vitro Studies:

• Cell Line Testing: Assess the effects of the mRNA and its encoded protein on various cell lines to identify potential cytotoxicity, genotoxicity, or other cellular impacts.

• Toxicology Screening: Conduct assays to evaluate how the protein affects cell viability, proliferation, and function.

**b. In Vivo Studies:

• Animal Models: Use animal studies to evaluate biodistribution, pharmacokinetics, and potential toxic effects of the mRNA therapy. This can help identify possible adverse effects before human exposure.

• Chronic Toxicity Studies: Monitor animals for extended periods to assess long-term effects and identify any delayed adverse outcomes.

**c. Bioinformatics:

• Protein Modeling: Predict the structure and function of the protein to identify potential risks, such as abnormal protein folding or interaction with other cellular components.

• Pathway Analysis: Use computational models to understand how the protein might influence cellular pathways and contribute to toxicity.

**2. Advanced Monitoring Techniques

**a. Biodistribution Studies:

• Imaging Technologies: Utilize advanced imaging techniques (e.g., PET, MRI) to monitor the distribution of the mRNA and its protein product within the body in real time.

• Biomarkers: Measure biomarkers that can indicate potential adverse effects or toxicity.

**b. Long-Term Animal Studies:

• Extended Observation: Continue to observe animals for extended periods to detect any long-term or delayed adverse effects that may not be evident in shorter-term studies.

**3. Regulatory and Safety Frameworks

**a. Regulatory Consultation:

• Pre-Submission Meetings: Engage with regulatory agencies (e.g., FDA, EMA) to discuss the proposed therapy and receive guidance on required safety assessments and regulatory pathways.

• Regulatory Guidelines: Follow guidelines for preclinical and clinical safety evaluations as outlined by regulatory bodies.

**b. Risk Management Plans:

• Contingency Planning: Develop comprehensive risk management plans, including strategies for monitoring and managing potential adverse effects.

**4. Ethical and Independent Review

**a. Ethics Committees:

• Review Boards: Obtain approval from independent ethics committees to ensure that safety assessments and study designs are rigorous and ethical.

• Informed Consent: Ensure that potential risks are communicated clearly to participants and that informed consent processes are thorough.

**5. Patient and Community Engagement

**a. Stakeholder Feedback:

• Patient Advocacy Groups: Engage with patient advocacy groups to gather feedback on potential risks and benefits from the perspective of those who might be affected by the therapy.

**b. Transparency:

• Data Sharing: Share findings from preclinical studies and other safety assessments with the scientific community to facilitate independent review and scrutiny.

**6. Risk-Benefit Analysis

**a. Weighing Risks and Benefits:

• Benefit-Risk Assessment: Conduct a thorough benefit-risk assessment to evaluate whether the potential benefits of the therapy outweigh the identified risks.

**b. Controlled Use:

• Early Access Programs: In some cases, therapies may be offered under controlled conditions (e.g., compassionate use or expanded access programs) with rigorous monitoring to manage and assess safety.

Limitations and Complementary Measures

• Clinical Trials: Despite the value of these measures, clinical trials are essential for obtaining comprehensive safety and efficacy data. They provide critical information on how the therapy performs in human subjects and helps to identify unforeseen adverse effects.

• Emerging Data: Continuous monitoring and post-marketing surveillance can provide additional safety data once the therapy is in use, helping to refine understanding of its long-term effects.

Summary

While preclinical research, advanced monitoring, regulatory frameworks, and ethical reviews are crucial for assessing the safety of an mRNA therapy, they cannot fully replace the insights gained from extensive clinical trials. Clinical trials are necessary to comprehensively evaluate the safety and efficacy of a new therapy in humans. In their absence, a combination of the above measures can provide valuable information and mitigate risks, but they should be considered as part of a broader, more cautious approach to ensure patient safety.

---

Question 8

So, in this absence of clinical trials to cover the extensive list of potential outcomes and if the proposed mRNA treatment were aimed to assist less than 1% of the population is it a good idea to apply such a mRNA treatment to over 80% of the Human population?

---

ChatGPT

In the absence of extensive clinical trials and with a proposed mRNA treatment intended to assist a small fraction of the population (less than 1%), applying the treatment to a large proportion of the population (over 80%) poses significant ethical, medical, and practical concerns. Here are the key considerations:

**1. Risk vs. Benefit Analysis

**a. Benefit to the Target Population:

• Targeted Treatment: If the mRNA therapy is highly beneficial for less than 1% of the population, the primary focus should be on ensuring that it is effective and safe for that specific group.

• Precision Medicine: Personalized or precision medicine approaches would be more appropriate for treating the small, targeted group that stands to benefit from the therapy.

**b. Potential Risks to the General Population:

• Unknown Side Effects: Without extensive clinical trials, the risks and potential side effects of the mRNA treatment in the general population are unknown. Introducing it to a large number of people could result in unforeseen adverse effects.

• Resource Allocation: There is a risk of misallocating resources and potentially causing harm to a large number of people if the therapy is not broadly applicable or safe.

**2. Ethical Considerations

**a. Informed Consent:

• Consent Process: Individuals must be fully informed about the potential risks and benefits of the treatment. Applying a treatment with unknown long-term effects to a large population without informed consent is ethically problematic.

• Equitable Access: Ensuring that the therapy is provided equitably and only to those who need it and have consented to its use is crucial.

**b. Equity and Fairness:

• Target Population Needs: If the therapy is intended for a small subset of the population, it should be carefully evaluated and administered to that group rather than broadly to a large population that may not benefit from it.

**3. Practical and Logistical Concerns

**a. Health System Impact:

• Healthcare Burden: Applying the treatment to a large population without sufficient evidence of safety and efficacy could place a significant burden on the healthcare system, including managing potential adverse effects.

• Monitoring and Management: Extensive monitoring would be required to track outcomes and manage any adverse effects, which could be challenging on a large scale.

**b. Public Trust:

• Trust in Medical Interventions: Broadly applying a treatment with insufficient evidence could undermine public trust in medical interventions and regulatory agencies. Transparency and thorough evidence are essential for maintaining confidence.

**4. Alternative Approaches

**a. Targeted Clinical Trials:

• Initial Focus: Conduct targeted clinical trials with a focus on the specific population that stands to benefit from the therapy. This approach provides critical safety and efficacy data while minimizing risks to the broader population.

**b. Phased Implementation:

• Gradual Rollout: Implement the treatment in phases, starting with a small, controlled group and gradually expanding based on the outcomes and safety data collected.

**c. Compassionate Use or Expanded Access:

• Specific Circumstances: In some cases, the treatment might be made available under compassionate use or expanded access programs, specifically for individuals who meet certain criteria and for whom no other options are available.

**5. Regulatory Oversight

**a. Regulatory Guidance:

• Compliance: Adhere to regulatory guidance and consult with regulatory agencies to determine the appropriate pathway for introducing the therapy, including any special conditions or safeguards required.

**b. Ongoing Evaluation:

• Post-Marketing Surveillance: If the treatment is introduced, implement robust post-marketing surveillance to monitor safety and efficacy and respond to any emerging issues.

Summary

Applying an mRNA treatment to over 80% of the population, particularly when it is intended for a small subset of people and in the absence of extensive clinical trials, is not advisable due to the significant risks and ethical issues involved. A more prudent approach involves targeted clinical trials, phased implementation, and careful consideration of ethical and practical concerns. Ensuring that treatments are safe and effective for their intended populations before broad application is essential for protecting public health and maintaining trust in medical interventions.

---

Question 9

How important is it that the regulators of such mRNA Medicines have an arm’s length relationship to the stakeholders of these mRNA Medicines and what degree of separation from any direct correspondence between regulators and mRNA medicines stakeholders would you recommend?

---

ChatGPT

An arm's-length relationship between regulators and stakeholders in the development and approval of mRNA medicines is crucial to ensure the integrity, objectivity, and credibility of the regulatory process. This separation helps maintain trust in the regulatory system and ensures that decisions are based on rigorous, unbiased scientific evidence rather than external influences or conflicts of interest. Here’s a detailed look at why this separation is important and how it should be managed:

**1. Importance of Arm's-Length Relationship

**a. Prevention of Conflicts of Interest:

• Objective Evaluation: Regulators must evaluate mRNA medicines based solely on scientific evidence and safety data. Close relationships with stakeholders could introduce biases or conflicts of interest that undermine the objectivity of the review process.

**b. Public Trust:

• Confidence in Decisions: Maintaining a clear separation helps ensure that regulatory decisions are perceived as impartial and based on rigorous scientific evaluation, which is essential for public confidence in the safety and efficacy of new medicines.

**c. Integrity of the Regulatory Process:

• Unbiased Decisions: An arm's-length relationship ensures that the regulatory process remains focused on protecting public health, without undue influence from commercial or other interests.

**2. Degree of Separation

**a. Regulatory Frameworks:

• Established Guidelines: Regulatory agencies often have established guidelines and protocols to manage interactions with stakeholders and ensure transparency. Adhering to these guidelines helps maintain appropriate boundaries.

**b. Transparency and Documentation:

• Disclosure of Interactions: All interactions between regulators and stakeholders should be documented and disclosed to the public to ensure transparency and accountability.

• Conflict of Interest Declarations: Regulators and advisory committee members should declare any potential conflicts of interest and recuse themselves from decisions where conflicts are present.

**c. Formal Communication Channels:

• Structured Processes: Formal, structured communication channels should be established for stakeholders to submit data, requests, or inquiries. This can include formal submissions through regulatory portals, public consultations, and scheduled meetings.

**d. Independent Review:

• External Advisors: Use independent experts and advisory committees to review data and provide recommendations. These advisors should be selected based on their expertise and free from conflicts of interest.

**e. Regulatory Decision-Making:

• Clear Separation: The decision-making process should involve multiple levels of review and oversight, ensuring that no single individual or group has undue influence over the final decision.

**3. Practical Recommendations

**a. Avoid Direct Correspondence:

• Indirect Communication: Regulators should avoid direct, informal correspondence with stakeholders and instead use formal channels. Any communication should be documented and accessible for transparency.

**b. Regular Audits and Reviews:

• Internal Audits: Conduct regular audits and reviews of the regulatory process to ensure adherence to guidelines and identify any potential issues related to stakeholder interactions.

**c. Training and Awareness:

• Regulatory Training: Provide training for regulators on managing conflicts of interest and maintaining professional boundaries.

**d. Public Engagement:

• Stakeholder Engagement: Engage with the public and stakeholders in a structured and transparent manner, ensuring that input is considered but does not influence the regulatory decisions unduly.

**4. Examples from Regulatory Practices

**a. FDA and EMA Practices:

• Transparency: Both the FDA (Food and Drug Administration) and EMA (European Medicines Agency) have established practices for managing interactions with stakeholders, including public disclosure of advisory committee meetings and conflict of interest policies.

**b. Advisory Committees:

• External Review: Use of external advisory committees to review data and make recommendations helps provide an additional layer of scrutiny and objectivity.

Summary

Maintaining an arm's-length relationship between regulators and stakeholders is essential for ensuring that the regulatory process for mRNA medicines is objective, unbiased, and transparent. This separation helps prevent conflicts of interest, maintains public trust, and ensures that decisions are based on rigorous scientific evaluation. Effective management of this relationship involves structured communication channels, transparency, independent review processes, and regular audits to ensure that regulatory decisions are made with the highest integrity and credibility.

End of Chat

---

Comments:

The mRNA vaccines were NOT a localized injection of an inert substance that remained in the deltoid muscle - they WERE( and ARE) synthetic Genetic Instructions with a body wide Biodistribution using Lipid Nano Paticles that in themselves are inflammatory.

Australia’s TGA knew , BEFORE they approved and released mRNA onto the Australian Population, that these Genetic Instructions would travel throughout the body and deliver their Genetic Instructions in a mesmerizingly extensive mosaic of different and sensitive cell types of the body. The proof of the TGA Prior Knowledge was exposed through a FOI showing a Pfizer document submitted to the Australian TGA in January of 2021.

See: https://www.tga.gov.au/sites/default/files/foi-2389-06.pdf

Related Post:

---

Google’s AI Gemini- Update Aug19, 2024

---

A Chat with Google’s AI Gemini yielded the following summary of discussions.
It should be noted that Google’s AI engine exhibited a much stronger Narrative aligned with Media , Big Pharmaceutical , Regulatory Authorities, Politicians and Advisory Committees. Even so with the right line of questioning the following summary of a conversation was made by Gemini

Text from Google AI Gemini quoted Verbatim

---

“Summary of Discussion: mRNA COVID-19 Vaccines

The discussion centered on the complexities and uncertainties surrounding the use of mRNA COVID-19 vaccines, with a particular focus on their potential risks and the justification for mandates.

Key Points:

• Uncertainties and Risks:

  • The long-term effects of mRNA vaccines, including their potential biodistribution and impact on cellular function, remain largely unknown.

  • The possibility of uncontrolled biodistribution of mRNA and subsequent spike protein production in various cell types, such as epithelial, connective, muscle, nervous, reproductive, endocrine, and sensory cells, raises concerns about potential adverse effects.

  • Determining the causal link between deaths or illnesses and either natural COVID-19 infection or vaccine-induced spike protein production is challenging due to overlapping symptoms and limited diagnostic tools.

• Mandates and Individual Rights:

  • A blanket mandate of mRNA vaccines for healthy individuals across all age groups is not justified based on the current evidence.

  • The precautionary principle suggests a cautious approach, balancing potential benefits against risks.

  • Individual autonomy and informed consent are essential considerations.

Conclusion:

Given the significant uncertainties about the long-term implications of mRNA vaccines, particularly regarding their biodistribution and potential impact on various cell types, a cautious approach is warranted. Mandating these vaccines for healthy individuals, who are generally at low risk of severe COVID-19, is not supported by the current evidence. A more nuanced strategy that prioritizes high-risk populations, emphasizes education and informed consent, and continues robust surveillance is essential.

Further research is needed to address the outstanding questions about mRNA vaccine safety and efficacy.”

---

**UPDATE 18-OCT-2024**
Many are now saying “If the above plethora of risk from uncontrolled Biodistribution of a Genetic instruction were not bad enough, and that the genetic instruction was to produce a toxic spike protein with an uncontrolled and unnatural duration of length; add to this gamble DNA Fragment Contaminations at over 130 times any previous acceptable limit.
This reckless Genetic mRNA rollout is now so absurd that criminal investigations should follow if Politicians, Judges, and Health Regulators continue to look away or support this deployment of Genetic time-bombs.”

Below video posted to YouTube and preserved here on Substack from YouTube so called "community guidelines"

Letter referred to: https://russellbroadbent.com.au/australiansdemandanswers/

DNA Contaminated Related Substack:

DNA CONTAMINATION, SV40 & CANCER

Share this Post via SMS:
https://tribeqr.com/v/chatgptmrnalottery

or

A link via Twitter (X):
SMS https://x.com/tniwef/status/1823689346320568339

Disclaimer:   All content is presented for educational and/or entertainment purposes only. Under no circumstances should it be mistaken for professional advice, nor is it at all intended to be taken as such. The contents simply reflect current newsworthy items on Covid that are freely available. It is subject to error and change without notice. The presence of a link to a website does not indicate approval or endorsement of that web site or any services, products, or opinions that may be offered by them.

Neither this Substack nor any of its principals or contributors are under any obligation to update or keep current the information contained herein.

Although the information contained is derived from sources which are believed to be reliable, they cannot be guaranteed.

Disclosure: We accept no advertising or compensation, and have no material connection to any products, brands, topics or companies mentioned anywhere on this post.

Fair Use Notice: This post may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. This post is making such material available in efforts to advance understanding of issues of social significance. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.